Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

27
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
27
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

376
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
376
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

514
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
514

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective exploratory pilot study of 18 F-FMISO PET/CT for assessing tumor hypoxia in soft tissue sarcomas.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same author

A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Response to the Comment on "Negative 18 F-FES PET/CT Despite Estrogen Receptor Positivity By Immunohistochemistry."

Clinical nuclear medicine·2026
Same author

Beyond Routine Surveillance Imaging for Melanoma: Emerging Technologies for Detecting Early Recurrence and Guiding Clinical Management.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Differential Response to <sup>177</sup>Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

The Advantages and Disadvantages of Same-Day Breast Imaging Services: Clinical Review, Implications, and Future Directions.

Journal of breast imaging·2026

Related Experiment Video

Updated: Mar 28, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.3K

Development of Companion Diagnostics.

David A Mankoff1, Christine E Edmonds1, Michael D Farwell1

  • 1Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Seminars in Nuclear Medicine
|December 22, 2015
PubMed
Summary
This summary is machine-generated.

Molecular imaging companion diagnostics offer a powerful way to guide precision cancer medicine. These methods assess treatment effectiveness across the whole body and detect early responses, improving targeted therapy selection.

More Related Videos

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

728
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K

Related Experiment Videos

Last Updated: Mar 28, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.3K
Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

728
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K

Area of Science:

  • Oncology
  • Medical Imaging
  • Pharmacology

Background:

  • Precision medicine relies on identifying therapeutic targets for individualized cancer treatment.
  • Current companion diagnostics primarily use in vitro assays on biopsy samples.
  • Molecular imaging offers complementary insights beyond traditional biopsy analysis.

Purpose of the Study:

  • To review the role of molecular imaging companion diagnostics in cancer therapy.
  • To explore predicting treatment response and measuring early pharmacodynamic effects.
  • To discuss probe development and clinical translation of molecular imaging diagnostics.

Main Methods:

  • Discussion of molecular imaging techniques for companion diagnostics.
  • Review of probe development strategies (small molecules, antibodies).
  • Analysis of clinical examples in breast cancer and HER2-targeted therapy.

Main Results:

  • Molecular imaging can assess cancer heterogeneity and early treatment response.
  • Predictive and pharmacodynamic imaging markers have been tested in human trials.
  • Examples include endocrine therapy and HER2-targeted therapy for breast cancer.

Conclusions:

  • Molecular imaging companion diagnostics hold significant promise for enhancing precision cancer therapy.
  • Further development and validation are needed for clinical integration.
  • Successful translation requires addressing challenges in probe development and multicenter trials.